{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:31:18Z","timestamp":1791329478811,"version":"4.3.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,6,21]],"date-time":"2006-06-21T00:00:00Z","timestamp":1150848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2006,11,7]]},"DOI":"10.1007\/s10549-006-9260-6","type":"journal-article","created":{"date-parts":[[2006,6,20]],"date-time":"2006-06-20T15:47:17Z","timestamp":1150818437000},"page":"273-284","source":"Crossref","is-referenced-by-count":219,"title":["Quality of Life of Postmenopausal Women in the ATAC (\u201cArimidex\u201d, Tamoxifen, Alone or in Combination) Trial after Completion of 5\u00a0years' Adjuvant Treatment for Early Breast Cancer"],"prefix":"10.1007","volume":"100","author":[{"given":"David","family":"Cella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Cuzick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gershon","family":"Locker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the ATAC Trialists\u02019 Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,6,21]]},"reference":[{"key":"9260_CR1","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u02019 Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"9260_CR2","doi-asserted-by":"crossref","unstructured":"The ATAC Trialists\u02019 Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131\u20132139","DOI":"10.1016\/S0140-6736(02)09088-8"},{"key":"9260_CR3","doi-asserted-by":"crossref","unstructured":"ATAC Trialists\u02019 Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5\u00a0years\u02019 adjuvant treatment for breast cancer. Lancet 365:60\u201362","DOI":"10.1016\/S0140-6736(04)17666-6"},{"key":"9260_CR4","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1200\/JCO.2005.11.181","volume":"23","author":"TJ Whelan","year":"2005","unstructured":"Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5\u00a0years of tamoxifen in postmenopausal women. J Clin Oncol 23:6931\u20136940","journal-title":"J Clin Oncol"},{"key":"9260_CR5","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2004.08.029","volume":"22","author":"L Fallowfield","year":"2004","unstructured":"Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22:4261\u20134271","journal-title":"J Clin Oncol"},{"key":"9260_CR6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","volume":"15","author":"MJ Brady","year":"1997","unstructured":"Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G (1997) Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15:974\u2013986","journal-title":"J Clin Oncol"},{"key":"9260_CR7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570\u2013579","journal-title":"J Clin Oncol"},{"key":"9260_CR8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1006263818115","volume":"55","author":"LJ Fallowfield","year":"1999","unstructured":"Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Research and Treatment 55:189\u2013199","journal-title":"Breast Cancer Research and Treatment"},{"key":"9260_CR9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jclinepi.2004.01.012","volume":"57","author":"DT Eton","year":"2004","unstructured":"Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC (2004) A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 57:898\u2013910","journal-title":"J Clin Epidemiol"},{"key":"9260_CR10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0163278705275340","volume":"28","author":"KJ Yost","year":"2005","unstructured":"Yost KJ, Eton DT (2005) Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 28:172\u2013191","journal-title":"Eval Health Prof"},{"key":"9260_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/annonc\/mdj044","volume":"17","author":"L Fallowfield","year":"2006","unstructured":"Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C, Morris R, Price M (2006) Patients\u02019 preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17:205\u2013210","journal-title":"Ann Oncol"},{"key":"9260_CR12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2001.19.2.322","volume":"19","author":"S Demissie","year":"2001","unstructured":"Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322\u2013328","journal-title":"J Clin Oncol"},{"key":"9260_CR13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081\u20131092","journal-title":"N Engl J Med"},{"key":"9260_CR14","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2005.03.3654","volume":"24","author":"LJ Fallowfield","year":"2006","unstructured":"Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E (2006) Quality of Life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3\u00a0years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 24:910\u2013917","journal-title":"J Clin Oncol."},{"key":"9260_CR15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/978-3-642-55647-0_9","volume":"163","author":"J Cuzick","year":"2003","unstructured":"Cuzick J (2003) Aromatase inhibitors in prevention \u2013 data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163:96\u2013103","journal-title":"Recent Results Cancer Res"},{"key":"9260_CR16","unstructured":"National Comprehensive Cancer Network: NCCN practice guidelines in oncology v.1.2005: breast cancer. http:\/\/www.nccn.org 2005"},{"key":"9260_CR17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","volume":"23","author":"EP Winer","year":"2005","unstructured":"Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619\u2013629","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-006-9260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-006-9260-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-006-9260-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:28:42Z","timestamp":1559233722000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-006-9260-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,21]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,11,7]]}},"alternative-id":["9260"],"URL":"https:\/\/doi.org\/10.1007\/s10549-006-9260-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,21]]}}}